Answers are grounded in this paper and cite their sources.
Metastasis, which accounts for approximately 90 % of cancer-related mortality, is driven by intricate regulatory networks that remain only partially understood. MicroRNA-150 (miR-150) has emerged as a pivotal, context-dependent regulator within these networks, displaying dual functionality as either a tumor suppressor or an oncogene, depending on tumor type, isoform (-5p/-3p), and microenvironmental cues. This comprehensive review synthesizes evidence highlighting miR-150's regulation of critical metastatic processes-namely epithelial-mesenchymal transition, cell migration, invasion, extracellular matrix remodeling, and angiogenesis-through direct targeting of key molecular effectors and its dynamic integration into competitive endogenous RNA (ceRNA) networks involving long non-coding RNAs and circular RNAs. Notably, miR-150 primarily acts as a metastasis suppressor in solid tumors, such as breast, colorectal, and ovarian cancers, by inhibiting pro-metastatic signaling pathways. However, it paradoxically facilitates metastatic progression in specific contexts, including non-small cell lung cancer and cervical carcinoma, by activating oncogenic cascades through suppression of tumor suppressors. Clinically, reduced miR-150 expression serves as a robust indicator of advanced disease stage, lymph node involvement, and poor prognosis, while circulating exosomal miR-150 shows promise as a non-invasive diagnostic biomarker. Therapeutically, tailored strategies employing miR-150 mimics, antagomiRs, or ceRNA-targeted inhibitors hold potential for disrupting metastatic pathways; however, challenges such as isoform-specific targeting, precise delivery, and mitigation of off-target effects remain unresolved. In our view, framing miR-150 as a "double-edged sword" in metastatic regulation provides a conceptual framework for leveraging its molecular versatility to advance precision oncology and mitigate metastatic progression, particularly in combination with emerging systemic therapies.
No takes yet. Share an insight, caveat, or question.
Almajali et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: